top of page

MEMO Therapeutics closes financing round of CHF 5 million

MEMO Therapeutics has secured a CHF 5 million Series A funding round

Congratulations to our portfolio company MEMO Therapeutics (RACII) for securing CHF 5 million of fresh capital in its financing round. Redalpine and existing investors contributed to the oversubscribed round, which was joined by Schroder Adveq and further new investors.

The funding will be used to further develop the proprietary MemoMABTM technology platform to capture and screen entire antibody repertoires, as well as to advance MEMO’s antibody candidates in the fields of immuno-oncology and infectious diseases towards preclinical and clinical investigation.

MEMO's Chief Executive Officer Dr. Christoph Esslinger commented: “We are very pleased that we could attract new investors including the internationally renowned venture firm Schroder Adveq to invest into MEMO." Dr. Dragan Grabulovski,

MEMO's key strategic advisor and former Chief Scientific Officer of Covagen added: "The funding provided by the investors validates the interest in the MemoMABTM technology and will allow MEMO to progress quickly towards generating key proof of principle data for the lead drug candidates.”

Redalpine congratulates MEMO Therapeutics and the entire team on this exciting milestone.  

Read more about it on the MEMO blog.


bottom of page